Protagonist Therapeutics Inc (PTGX)

$30.74 1.20 (3.76%)

16:00 EDT PTGX Stock Quote Delayed 30 Minutes

PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024

By InvestorPlace Earnings May 7, 2024

PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

3 Biotech Stocks to Buy Before They Boom

7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years

Volume:

Previous Close -

Market Cap 1.80B

PE Ratio 12.20

EPS 2.52

Volume (Avg. Vol.) 441,376

Day's Range $30.64 - $32.14

52-Week Range $13.72 - $33.34

Dividend & Yield N/A (N/A)

PTGX Stock Predictions, Articles, and Protagonist Therapeutics Inc News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Apr 14, 2022

The biggest pre-market stock movers for Thursday are ready and waiting so let's see what's moving the market this morning!

3 Desirable Drug Stocks With Very Promising Pipelines

By Larry Ramer, InvestorPlace Contributor Feb 16, 2022

Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.

Short Squeeze Stocks: PTGX, AGC and 3 Others Experts Think Are Ready to Pop

By Chris MacDonald, InvestorPlace Contributor Oct 25, 2021

Here are five short squeeze stocks many investors are putting on their radar right now as a result of higher short interest and borrow fees.

PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today

By William White, InvestorPlace Writer Oct 11, 2021

Protagonist Therapeutics (PTGX) stock is rocketing higher on Monday thanks to an update from the FDA concerning rusfertide clinical studies.

Battered Protagonist Therapeutics Stock Is Primed For a Dip-Buy

By David Moadel, InvestorPlace Contributor Oct 5, 2021

When Wall Street overreacts to a news catalyst, contrarian traders can step in to take advantage of a rare opportunity now with PTGX stock.

PTGX Stock: Why Protagonist Therapeutics Is Plunging 60% Today

By Chris MacDonald, InvestorPlace Contributor Sep 17, 2021

Today, investors in Protagonist Therapeutics and PTGX stock have seen an absolutely massive decline due to an FDA hold of its clinical trial.

Protagonist Stock Jumps 58% After Re-Review of Test Results

By Chris Lau, InvestorPlace Contributor Aug 8, 2018

A re-review of the PTG-100 results undid the bad news of a discontinuation of Protagonist's clinical study. If the FDA allows the company to run Phase 2/3 studies for PTG-100, then the stock will continue its bounce higher.

Western Refining, Inc. (WNR) Signet Jewelers Ltd. (SIG) Leads 16 Activist Investor Filings

By Fintel Jun 2, 2017

13D and 13G filings are windows into activist investor activity. Today we focus on Western Digital and 15 other filings

Protagonist Therapeutics stock rises on Takeda license deal (NYSE:TAK)

From Seeking Alpha Feb 1, 2024

Protagonist Therapeutics shares surge as it enters a global collaboration with Takeda for the development of its investigational drug, rusfertide.

Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On

From The Motley Fool Nov 16, 2023

Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.

Are (More) Big Gains Ahead for This Small Cap Biotech Stock?

From MarketBeat Jun 28, 2023

With Biomea Fusion's share price nearly halved recently, oversold conditions seem to be setting in. This could be an opportunity for small cap growth investors.

Why Shares of Protagonist Therapeutics Rose This Week

From The Motley Fool Apr 21, 2023

The company's lead pipeline candidate is making news.

Protagonist Therapeutics prices $100M offering (NASDAQ:PTGX)

From Seeking Alpha Apr 5, 2023

Protagonist Therapeutics (PTGX) prices its public offering of 5M shares at a public offering price of $20.00 per share.Gross proceeds are expected to be $100M.Underwriters a 30-day...

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Polynovo Limited (OtherCALZF)

From TipRanks Dec 7, 2022

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Protagonist Therapeutics (PTGX – Research Report) an...

Protagonist Therapeutics Inc (PTGX)

PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

3 Biotech Stocks to Buy Before They Boom

7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Protagonist Therapeutics Inc (PTGX)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

PTGX Stock Predictions, Articles, and Protagonist Therapeutics Inc News

Subscriber Sign in